Biohaven epilepsy drug suffers FDA hold days after $350M deal
Biohaven epilepsy drug suffers FDA hold days after $350M deal — latest biotechnology news.
Biohaven
Biohaven is a clinical-stage biopharmaceutical company developing therapies for neurological and neuropsychiatric diseases. Following the spin-off of its commercial migraine portfolio to Pfizer, Biohaven is advancing next-generation neuroscience programs including IGF-1 targeted therapies and rare disease programs.
Company Info
Sector:Neuroscience / Neurology
Headquarters:New Haven, Connecticut, USA
Founded:2014
Website:www.biohaven.com/
Upcoming Milestones & Key Dates
2026-Q4
Clinical
BHV-7000 Phase 3 topline data in focal epilepsy
2026-Q3
Corporate
Scientific leadership transition (per ARPA-H/biohaven news)
Clinical Development Pipeline
BHV-7000
Target: Kv7.2/7.3 activatorBHV-8000
Target: TYK2/JAK1Taldefgrobep alfa
Target: MyostatinRecent News
FDA places partial hold on Biohaven's epilepsy drug
News from BioPharma Dive: FDA places partial hold on Biohaven's epilepsy drug
Biohaven trades cash for 'upside' with $795M epilepsy drug deal
Biohaven trades cash for 'upside' with $795M epilepsy drug deal
Biohaven could get up to $795M in epilepsy alliance with SK Bio
Biohaven could receive up to $795 million through an epilepsy drug alliance with South Korea's SK Biopharmaceuticals.
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
Leadership Team
Vlad Coric, MD
Chairman & CEO
Matthew Buten
Chief Financial Officer
Irfan Qureshi, MD
Chief Medical Officer